keyword
MENU ▼
Read by QxMD icon Read
search

Lamivudine

keyword
https://www.readbyqxmd.com/read/28731907/oral-nucleos-t-ide-analogs-alone-after-liver-transplantation-in-chronic-hepatitis-b-with-preexisting-rt204-mutation
#1
James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Sui-Ling Sin, Tan-To Cheung, Wing-Chiu Dai, Kelvin Ng, Kevin Ng, Kwan Man, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Chung-Mau Lo
BACKGROUND: There is currently limited data regarding the use of oral antiviral therapy alone without HBIG for CHB patients with preexisting LAM-resistance (LAM-R) undergoing liver transplantation. METHODS: This is a cohort study determining the effectiveness and long-term outcome in this group of patients. RESULTS: Fifty-seven consecutive CHB patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM undergoing liver transplantation were included, with a median follow-up of 73 months...
July 21, 2017: Transplantation
https://www.readbyqxmd.com/read/28729158/fixed-dose-combination-dolutegravir-abacavir-and-lamivudine-versus-ritonavir-boosted-atazanavir-plus-tenofovir-disoproxil-fumarate-and-emtricitabine-in-previously-untreated-women-with-hiv-1-infection-aria-week-48-results-from-a-randomised-open-label-non-inferiority
#2
Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Vicenç Falcó, Choy Y Man, Alicia Aylott, Ann M Buchanan, Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y Smith
BACKGROUND: Dolutegravir is a once-daily integrase strand transfer inhibitor with no need for pharmacokinetic boosting that is approved for the treatment of HIV-1 infection. Because women are often under-represented in HIV clinical trials, we addressed the safety and efficacy of dolutegravir in women with HIV-1. METHODS: The ARIA study is a randomised, open-label, multicentre, active-controlled, parallel-group, non-inferiority phase 3b study done in 86 hospital and university infectious disease clinics, local health clinics, and private infectious disease clinics in 12 countries and one US territory, in North America, South America, Europe, Africa, and Asia...
July 17, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28701257/physician-testing-for-hiv-in-patients-treated-with-tenofovir-disoproxil-fumarate-and-lamivudine-monotherapy-for-hepatitis-b-virus
#3
Jillian S Y Lau, Dilip Ratnam, Ian Woolley
Previously we found that local patients were often not tested for HIV prior to commencing nucleoside/nucleotide reverse transcription inhibitor (NRTI) therapy for hepatitis B virus. We performed a national cross-sectional cohort study of physician practices via an online survey. A small majority (23/44; 52%) of participants reported always testing their hepatitis B virus patients for HIV prior to NRTI therapy, and 8/44 (18%) reported testing for HIV the majority of the time. Thirteen (30%) respondents reported testing only if risk factors were present...
July 13, 2017: Sexual Health
https://www.readbyqxmd.com/read/28696345/optimal-hiv-postexposure-prophylaxis-regimen-completion-with-single-tablet-daily-elvitegravir-cobicistat-tenofovir-disoproxil-fumarate-emtricitabine-compared-with-more-frequent-dosing-regimens
#4
Kenneth H Mayer, Daniel Jones, Catherine Oldenburg, Sachin Jain, Marcy Gelman, Shayne Zaslow, Chris Grasso, Matthew J Mimiaga
STRUCTURE: The study evaluated elvitegravir/cobicistat/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) ("Quad pill") for postexposure prophylaxis (PEP). BACKGROUND: HIV-exposed individuals may benefit from PEP, but completion rates have been suboptimal because of regimen complexity and side effects. Newer antiretroviral combinations coformulated as single daily pills may optimize PEP adherence. SETTING: One hundred HIV-uninfected individuals who presented to a Boston community health center after an acute HIV sexual exposure were enrolled and initiated PEP with the daily, single-pill combination Quad pill for a 28-day course...
August 15, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28696229/mdr1-and-bcrp-transporter-mediated-drug-drug-interaction-between-rilpivirine-and-abacavir-effect-on-intestinal-absorption
#5
Josef Reznicek, Martina Ceckova, Zuzana Ptackova, Ondrej Martinec, Lenka Tupova, Lukas Cerveny, Frantisek Staud
Rilpivirine (TMC278) is a highly potent second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) representing an effective component of combination antiretroviral therapy (cART) in the treatment of HIV-positive patients. Many antiretroviral drugs commonly used in cART are substrates of ATP-binding cassette (ABC) and/or solute carrier (SLC) drug transporters and, therefore, prone to pharmacokinetic drug-drug interactions (DDIs). The aim of our study was to evaluate rilpivirine interactions with abacavir and lamivudine on selected ABC and SLC transporters in vitro and assess its importance for pharmacokinetics in vivoUsing accumulation assays in MDCK cells overexpressing selected ABC or SLC drug transporters we revealed rilpivirine as a potent inhibitor of MDR1 and BCRP, but not MRP2, OCT1, OCT2 or MATE1...
July 10, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28691231/active-immunization-for-prevention-of-de-novo-hbv-infection-after-adult-living-donor-liver-transplantation-with-hbc-graft
#6
Shih-Ho Wang, Poh-Yen Loh, Ting-Lung Lin, Li-Man Lin, Wei-Feng Lee, Yu-Hung Lin, Chih-Che Lin, Chao-Long Chen
Background De novo hepatitis B infection (DNHB) may occur in recipients who do not receive prophylaxis after liver transplantation (LT) with anti-HBc(+) donor grafts. Active immunization has been shown to prevent DNHB in pediatric recipients. Our aim is to investigate the efficacy of HBV vaccination for preventing DNHB in adult living donor LT (LDLT). Patients and Methods 71 adult HBsAg(-) LDLT patients who received anti-HBc(+) grafts from 2000 to 2010 were enrolled into this study. Patients were given HBV vaccinations with the aim of achieving anti-HBs >1000 IU/L pre-transplant and >100 IU/L post-transplant...
July 10, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28686654/a-retrospective-case-cohort-study-comparing-treatment-outcomes-in-abacavir-versus-stavudine-containing-first-line-antiretroviral-treatment-regimens-in-children-3yrs-old-at-a-paediatric-programme-based-in-soweto-south-africa
#7
Haseena Cassim, Kennedy Otwombe, Erica Lazarus, Afaaf Liberty, Glenda E Gray, Oppel B W Greeff, Avy Violari
INTRODUCTION: The current World Health Organization guideline for first line antiretroviral therapy (ART) in HIV-infected children recommends the use of abacavir and lamivudine as nucleoside backbones and no longer includes stavudine. We compared treatment outcomes with abacavir (ABC) versus stavudine (d4T) in a cohort of HIV-1 infected children 6 and 12 months after antiretroviral therapy was initiated. METHODS: This was a retrospective case-cohort study, using programmatic data from children enrolled in the Paediatric Wellness Programme at the Perinatal HIV Research Unit in Soweto, South Africa between 2005 and 2013...
2017: PloS One
https://www.readbyqxmd.com/read/28676264/in-vivo-genotoxicity-evaluation-of-efavirenz-efv-and-tenofovir-disoproxil-fumarate-tdf-alone-and-in-their-clinical-combinations-in-drosophila-melanogaster
#8
Aroldo Vieira de Moraes Filho, Cláudia de Jesus Silva Carvalho, Cícero Jorge Verçosa, Macks Wendhell Gonçalves, Cláudia Rohde, Daniela de Melo E Silva, Kênya Silva Cunha, Lee Chen-Chen
This study focuses on the antiretrovirals efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and tenofovir disoproxil fumarate (TDF), an oral prodrug of tenofovir analog of adenosine 5'-monophosphate, which belongs to the class of nucleotide reverse transcriptase inhibitors. Both compounds act on the mechanisms of HIV replication, inhibiting the action of reverse transcriptase and thus preventing viral DNA synthesis. The toxic and genotoxic potential of EFV and TDF alone and in combinations {EFV+combivir [zidovudine (AZT)+lamivudine (3TC)] and TDF+3TC} were assessed using the comet assay and the somatic mutation and recombination test (SMART) in Drosophila melanogaster...
August 2017: Mutation Research
https://www.readbyqxmd.com/read/28671553/the-ultra-short-virological-dynamics-in-response-to-entecavir-or-lamivudine-during-chronic-hepatitis-b-with-spontaneous-severe-acute-exacerbation
#9
Teng-Yu Lee, Chi-Yi Chen, Hsueh-Chou Lia, Yu-Chung Hsu, Sheng-Shun Yang
BACKGROUND: Nucleos(t)ide analogue (NA) therapy could be life-saving in chronic hepatitis B (CHB) with spontaneous severe acute exacerbation (SAE). We aimed to investigate the ultra-short virological responses to NA. METHODS: We conducted a randomized controlled trial in which CHB patients with spontaneous SAE were randomized to receive lamivudine (LVD) or entecavir (ETV) between July 2012 and April 2016 (ClinicalTrials.gov: NCT01627223). The serum hepatitis B virus (HBV) viral loads on day 1 (baseline), 3, 5, 8, 15, 22, 29, 85, and 180 after initiating NA therapy were checked and analyzed...
July 3, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28669175/efficacy-of-tenofovir-based-rescue-therapy-for-chronic-hepatitis-b-patients-with-resistance-to-lamivudine-and-entecavir
#10
Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin
Background/Aims: Tenofovir disoproxil fumarate (TDF) monotherapy for 48 weeks provided a virological response comparable to that of TDF and entecavir (ETV) combination therapy in patients infected with ETV-resistant hepatitis B virus (HBV). Little long-term data in routine clinical practice are available regarding the optimal treatment of patients with ETV-resistant HBV. Methods: We investigated the long-term antiviral efficacy of combination therapy of TDF+lamivudine (LAM) or TDF+ETV compared to that of TDF monotherapy in 73 patients with resistance to both LAM and ETV...
June 30, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28659333/failure-of-long-term-lamivudine-prophylaxis-in-patients-with-resolved-hepatitis-b-infection-undergoing-chemotherapy-and-allogenic-hematopoietic-stem-cell-transplantation-for-hematological-malignancies-two-case-reports
#11
Glenda Grossi, Mauro Viganò, Floriana Facchetti, Sara Labanca, Alessandro Loglio, Anna Dodero, Vittorio Montefusco, Paolo Corradini, Anna Cafro, Roberto Cairoli, Massimo Colombo, Pietro Lampertico
No abstract text is available yet for this article.
June 28, 2017: Haematologica
https://www.readbyqxmd.com/read/28655306/multi-state-models-for-the-analysis-of-time-to-treatment-modification-among-hiv-patients-under-highly-active-antiretroviral-therapy-in-southwest-ethiopia
#12
Belay Birlie, Roel Braekers, Tadesse Awoke, Adetayo Kasim, Ziv Shkedy
BACKGROUND: Highly active antiretroviral therapy (HAART) has shown a dramatic change in controlling the burden of HIV/AIDS. However, the new challenge of HAART is to allow long-term sustainability. Toxicities, comorbidity, pregnancy, and treatment failure, among others, would result in frequent initial HAART regimen change. The aim of this study was to evaluate the durability of first line antiretroviral therapy and to assess the causes of initial highly active antiretroviral therapeutic regimen changes among patients on HAART...
June 27, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28651173/development-validation-and-clinical-application-of-a-method-for-the-simultaneous-quantification-of-lamivudine-emtricitabine-and-tenofovir-in-dried-blood-and-dried-breast-milk-spots-using-lc-ms-ms
#13
Catriona Waitt, Sujan Diliiy Penchala, Adeniyi Olagunju, Alieu Amara, Laura Else, Mohammed Lamorde, Saye Khoo
OBJECTIVES: To present the validation and clinical application of a LC-MS/MS method for the quantification of lamivudine (3TC), emtricitabine (FTC) and tenofovir (TFV) in dried blood spots (DBS) and dried breast milk spots (DBMS). METHODS: DBS and DBMS were prepared from 50 and 30μL of drug-spiked whole blood and human breast milk, respectively. Following extraction with acetonitrile and water, chromatographic separation utilised a Synergi polar column with a gradient mobile phase program consisting of 0...
June 17, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28646196/nucleoside-reverse-transcriptase-inhibitors-nrtis-induce-proinflammatory-cytokines-in-the-cns-via-wnt5a-signaling
#14
Ting Wu, Juan Zhang, Mingxing Geng, Shao-Jun Tang, Wenping Zhang, Jianhong Shu
HAART is very effective in suppressing HIV-1 replication in patients. However, patients staying on long-term HAART still develop various HIV-associated neurological disorders, even when the viral load is low. The underlying pathogenic mechanisms are largely unknown. Emerging evidence implicated that persistent neuroinflammation plays an important role in NeuroAIDS. Although residual virus or viral proteins are commonly thought as the causal factors, we are interested in the alternative possibility that HAART critically contributes to the neuroinflammation in the central nervous system (CNS)...
June 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28640661/attrition-from-antiretroviral-treatment-services-among-pregnant-and-non-pregnant-patients-following-adoption-of-option-b-in-haiti
#15
Jean Wysler Domercant, Nancy Puttkammer, Paul Young, Krista Yuhas, Kesner François, Reynold Grand'Pierre, David Lowrance, Michelle Adler
BACKGROUND: Access to antiretroviral therapy (ART) has expanded in Haiti because of the adoption of Option B+ and the revision of treatment guidelines. Retention in care and treatment varies greatly and few studies have examined retention rates, particularly among women enrolled in Option B+. OBJECTIVE: To assess attrition among pregnant and non-pregnant patients initiating ART following adoption of Option B+ in Haiti. METHODS: Longitudinal data of adult patients initiated on ART from October 2012 through August 2014 at 73 health facilities across Haiti were analyzed using a survival analysis framework to determine levels of attrition...
2017: Global Health Action
https://www.readbyqxmd.com/read/28638661/efficacy-and-tolerability-of-tenofovir-disoproxil-fumarate-based-regimen-as-compared-to-zidovudine-based-regimens-a-systematic-review-and-meta-analysis
#16
REVIEW
Tegene Legese Dadi, Adane Teshome Kefale, Teshale Ayele Mega, Muktar Sano Kedir, Habtamu Acho Addo, Tessema Tsehay Biru
BACKGROUND: Although tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) and zidovudine (ZDV)/lamivudine (3TC)/efavirenz (EFV) are used as preferred first line regimen, their head-to-head comparison in terms of their efficacy and tolerability was limited. This review aimed to synthesize the best available evidence on the comparative efficacy and tolerability of the two regimens. METHODS: Seven sites and databases in addition to Google search until August 20, 2016, were searched...
2017: AIDS Research and Treatment
https://www.readbyqxmd.com/read/28633752/rituximab-administration-in-a-patient-with-pemphigus-vulgaris-following-reactivation-of-occult-hepatitis-b-virus-infection
#17
Soheil Tavakolpour, Tahereh Soori, Pedram Noormohammadpour, Kamran Balighi, Hamidreza Mahmoudi, Maryam Daneshpazhooh
Immunosuppressive drugs are the milestone of treatment of autoimmune diseases, but they can lead to serious complications, including hepatitis B virus reactivation in HBV carriers as well as in patients with occult HBV infection (OBI). A 36-year-old man with OBI was diagnosed with pemphigus vulgaris. He was prescribed prednisolone and his hepatitis B surface antigen turned positive. Viral replication was successfully controlled by lamivudine and adefovir. Mycophenolate mofetil and intravenous immunoglobulin  were not effective in controlling the pemphigus vulgaris...
June 20, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28627771/clinical-experience-with-the-integrase-inhibitors-dolutegravir-and-elvitegravir-in-hiv-infected-patients-efficacy-safety-and-tolerance
#18
Purificación Cid-Silva, Josep M Llibre, Noelia Fernández-Bargiela, Luis Margusino-Framiñán, Vanesa Balboa-Barreiro, Berta Pernas-Souto, Isabel Martín-Herranz, Ángeles Castro-Iglesias, Eva Poveda
Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of these INSTIs in the last two years. A retrospective observational study in patients who started DTG or EVG/COBI from January 2015 to January 2017 at a reference hospital in north-western Spain was done. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed with SPSS software...
June 19, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28627427/efficacy-and-safety-of-a-once-daily-single-tablet-regimen-of-tenofovir-lamivudine-and-efavirenz-assessed-at-144-weeks-among-antiretroviral-na%C3%A3-ve-and-experienced-hiv-1-infected-thai-adults
#19
Anchalee Avihingsanon, Wirach Maek-A-Nantawat, Sivaporn Gatechompol, Vorapot Sapsirisavat, Wanida Thiansanguankul, Jiratchaya Sophonphan, Narujakorn Thammajaruk, Sasiwimol Ubolyam, David M Burger, Kiat Ruxrungtham
OBJECTIVE: To assess the efficacy and safety of a new single-tablet regimen (STR) of tenofovir disoproxil fumarate (TDF) 300mg, lamivudine (3TC) 300mg, and efavirenz (EFV) 600mg in HIV-infected Thai patients. METHODS: This was a prospective study performed for 144 weeks among 51 treatment-naïve patients and 49 experienced patients on separate tablets of TDF, 3TC, and EFV with HIV RNA<50 copies/ml. CD4, HIV RNA, liver and renal function, and lipid profiles were assessed at baseline, weeks 12, 24, and 48, and then every 24 weeks...
June 13, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28624823/effect-of-interferon-%C3%AE-and-combined-interferon-%C3%AE-with-lamivudine-treatment-on-anthropometric-measurements-in-children-with-chronic-hepatitis-b
#20
Nafiye Urganci, Derya Kalyoncu, Ela Erdem Eralp
No abstract text is available yet for this article.
June 17, 2017: Annals of Nutrition & Metabolism
keyword
keyword
114587
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"